New hope for elderly leukemia patients: study tests gentler chemo combo
NCT ID NCT07132684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a newer, targeted drug combination (venetoclax plus azacitidine) works better than standard intensive chemotherapy for adults aged 55 to 75 with acute myeloid leukemia (AML). About 240 participants will be randomly assigned to one of the two treatments. The main goal is to see which approach helps people live longer, with fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can targeted drug cocktails erase hidden leukemia cells?
- Could early comfort care change End-of-Life for blood cancer patients?
- New cocktail targets tough leukemia mutations
- New Triple-Drug attack on aggressive leukemia shows promise in major trial
- Immune cells take on tough leukemia in early trial
- Blood transfusions guided by how you feel, not just lab numbers